About Plexus Ventures
Plexus Ventures is a venture capital firm founded in 1990. It is primarily based out of Ambler, United States. It primarily invests in Japan based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Overall, Plexus Ventures portfolio has seen 10 IPOs and 3 acquisitions including key companies like Eisai, Astrazeneca and ProQR Therapeutics. Plexus Ventures has team of 11 people including 3 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio IPOs
Portfolio Acquisitions
Plexus Ventures' List of Top Investments
Plexus Ventures has a portfolio of 19 companies. Their most notable investments include Eisai and Astrazeneca.Their portfolio spans across Japan, Italy, Netherlands and 10 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors. Here is the list of top investments by Plexus Ventures:
1. Eisai
Developer of drugs for oncology and neurological disorders. The company's products include ciphex/Pariet (rabeprazole) for Gastroesophageal reflux disease, Actonel (risedronic acid) for Osteoporosis, Aloxi (palonosetron) for Chemotherapy-induced nausea and vomiting, Aricept (donepezil) for Alzheimer's Disease, Banzel/Inovelon (rufinamide) for seizures related to Lennox for gastaut syndrome, Belviq (lorcaserin) for obesity, Fragmin (dalteparin) for deep vein thrombosis and pulmonary embolism, and more.
Key facts about Eisai
- Founded Year: 1941
- Location: Jakarta (Indonesia)
- Stage: Public
- Employee Count: 2,813 as on Dec 06, 2025
- Investors: Petrillo Capital, Plexus Ventures and 3 Others
- Latest Funding Round: Grant (prize money), Jan 28, 2025, $*****
- Highlight: Public
2. Astrazeneca
Developer of medicines in oncology, biopharmaceuticals, and rare disease areas. It focuses on research and development of therapeutic products. The company's pipeline includes various projects in different phases of development. It provides resources and information for investors, media, and those seeking partnerships.
Key facts about Astrazeneca
- Founded Year: 1913
- Location: Cambridge (United Kingdom)
- Stage: Public
- Employee Count: 77,554 as on Jan 01, 2026
- Investors: Digital Pharma Lab, Investor and 12 Others
- Latest Funding Round: Post IPO, Dec 27, 2021, $*****
- Highlight: Public
Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders. The company has designed therapeutic candidates to specifically target and repair the defective messenger RNA, (mRNA). Their proprietary technology known as Axiomer involves the use of single-stranded RNA-based oligonucleotides, which act as guide sequences to repair (single nucleotide changes to RNA) the targeted abnormal mRNA. The product pipeline includes QR-110, for Leber’s congenital amaurosis patients, QR-421 for mediated retinitis pigmentosa and Usher syndrome, QR-1123 for retinal mediated retinitis pigmentosa.
Key facts about ProQR Therapeutics
- Founded Year: 2012
- Location: Leiden (Netherlands)
- Stage: Public
- Total Funding till date: $58M
- Employee Count: 205 as on Jul 01, 2024
- Investors: Foresite Capital, Gilde Healthcare and 7 Others
- Latest Funding Round: Post IPO, Jul 14, 2020, $*****
- Highlight: Public
4. Merck
Provider of drug research and development services for multiple therapeutic areas. It delivers personalized treatments for serious diseases, and progressive treatment solutions. It also offers diagnostic, and cosmetic products, along with semiconductors and optoelectronics.
Key facts about Merck
- Founded Year: 1668
- Location: Darmstadt (Germany)
- Annual Revenue: €21B as on Dec 31, 2023
- Stage: Public
- Employee Count: 6,151 as on Mar 08, 2025
- Investors: Triodos Investment Management, Plexus Ventures and 5 Others
- Latest Funding Round: Grant (prize money), Aug 11, 2023, $*****
- Highlight: Public
5. GSK
Developer of pharmaceuticals and vaccines for various therapeutic areas. This company focuses on research and development, producing medicines and vaccines to treat respiratory, immunology and inflammatory diseases, oncology, HIV, and infectious diseases. Its operations encompass the entire drug development lifecycle, from research to clinical trials and commercialization. The company also emphasizes access to its products globally and works towards sustainable practices.
Key facts about GSK
- Founded Year: 1715
- Location: London (United Kingdom)
- Last Known Valuation: $*****
- Stage: Acquired
- Employee Count: 91,612 as on Jan 13, 2026
- Investors: Digital Pharma Lab, Elliott Management and 15 Others
- Latest Funding Round: Grant (prize money), Dec 29, 2023, $*****
- Highlight: Acquired
IPOs and Publicly Listed companies in Plexus Ventures' Portfolio
10 of Plexus Ventures' portfolio companies have become public. Celon Pharma got listed on the Warsaw Stock Exchange (WSE), in Feb 2017 and xBrane got listed on the Nordic and Baltic regions (NASDAQ OMX).Here are Plexus Ventures' portfolio companies that went public:
Filter this listCompany | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 16, 2017 | - | - | 1549 | |
Feb 03, 2016 | - | - | 7005 | |
Nov 06, 2015 | - | - | 1820 | |
Sep 18, 2014 | - | - | 3002 | |
Aug 10, 2010 | - | - | 7244 |
Acquired companies in Plexus Ventures' Portfolio
3 companies from Plexus Ventures' portfolio have been acquired. The most recent acquisition were Applied Pharma Research in May 2021 by Relief Therapeutics.Here are Plexus Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 04, 2021 | - | - | 3049 | |
Dec 03, 2018 | - | - | 5075 | |
Jul 17, 2014 | - | - | 4919 |
Team profile of Plexus Ventures
Plexus Ventures has a team of 11 members including 3 Partners and 2 Principals located in United Kingdom, Italy and 1 more location. Plexus Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in Plexus Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Milan | - | ||
Partner | - | - | - | |
Partner | London | - | ||
Principal | Germany | - | ||
Principal | Ascot | - |
